A pilot non-interaction study confirmed the high tolerability of Quercefit in individuals assuming antiplatelet agents, anticoagulants, or living with diabetes. Recent studies suggest positive results for Quercefit, Indena’s Phytosome formulation of quercetin, in terms of bioavailability, efficacy, and tolerability.
 
Quercefit is standardized quercetin and formulated with Phytosome, the food grade delivery system able to synergize the biological absorption of certain compounds, such as flavonoids. According to a published human pharmacokinetic study comparing the Indena extract to unformulated quercetin extracts, it proved to be up to 20 times more bioavailable and able to be used at lower dosages, preserving its profile of natural ingredient (Riva A. et al. Eur J Drug Metab Pharmacokinet, 2018).
 
Furthermore, the effectiveness of 250mg (twice a day) of the ingredient was found to be effective in a controlled human study conducted on amateur athletes practicing triathlon according to “Sprint” format (100 minutes for swimming 750 m + cycling 20 km + running 5 km) (Riva A. et al. Minerva Medica, 2018).Quercefit statistically maintained the body’s resistance by optimizing performance and recovery, offering support for muscle wellbeing after physical activity. 
 
To further confirm the positive safety profile of Quercefit, a pilot non-interference clinical study was conducted in order to investigate any interaction of this complementary and natural approach with common standard synthetic drugs, preventing any possible harmful effect. Even if additional studies should be needed to confirm the positive results, the clinical outcomes suggest that Quercefit does not alter the antiplatelet activity of the most common antiplatelet agents; has no impact on the international Normalized ratio (iNr) values in stable patients treated with warfarin or dabigatran; and does not influence the metabolic control of diabetic patients treated with metformin (Riva A et al. Minerva Cardioangiol, 2018).
 
The interaction with the antiplatelet therapy was assessed through the bleeding time (BT) test in 30 patients treated with acetylsalicylic acid, ticlopidine or clopidogrel before and after 10 days of supplementation with Quercefit. Interaction with anticoagulants was evaluated by measuring the iNr in 20 patients using warfarin or dabigatran before and after 20 days of supplementation with Quercetfit. Lastly, glycemia and glycated hemoglobin were measured in 12 diabetic patients treated with metformin and restricted diet before and after 20 days of supplementation with Quercefit. After 10 days of supplementation no significant difference was observed in mean BT in patients treated with acetylsalicylic acid, ticlopidine or clopidogrel at standard dosages. 
 
Similarly, after 20 days of supplementation, the iNr level among patients assuming warfarin or dabigatran was not statistically different from baseline. Lastly, no statistically significant difference in mean levels of glycemia and glycated hemoglobin was reported before and after 20 days of complementary administration of Quercefit in diabetic patients treated with metformin and restricted diet.